- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Cellectar Biosciences Inc (CLRB)
Track today's live Cellectar Biosciences (CLRB) share price, performance and key data on this page with our current NASDAQ:CLRB stock exchange information. Analyse interactive charts and historical data, check technical buy and sell signals in real time, and follow the Cellectar Biosciences share price on the NASDAQ exchange. Use the dropdown to switch exchange for the CLRB share price, head to our technical summary section, which provides analysis on Cellectar Biosciences share price buy/sell indicators using real-time data (or discuss the Cellectar Biosciences (CLRB) stock price today with other investors in the Cellectar Biosciences NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ:CLRB share price (ISIN: US15117F8804) to enhance your trading decisions with our free investment tools and resources.
What Is the Cellectar Biosciences Inc Share Price Today?
The Cellectar Biosciences share price today is 2.6100.
What Is the Stock Symbol for Cellectar Biosciences Inc
The stock symbol (or 'ticker') for Cellectar Biosciences Inc is "CLRB."
What Stock Exchange Does Cellectar Biosciences Inc Trade On?
Cellectar Biosciences Inc is listed and trades on the NASDAQ stock exchange.
Is Cellectar Biosciences Inc a Good Stock to Buy?
Determining whether Cellectar Biosciences (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Use the dropdown to select a relevant stock exchange for the current NASDAQ:CLRB share price (ISIN: US15117F8804) to enhance your trading decisions with our free investment tools and resources.
What Is the Cellectar Biosciences Inc Share Price Today?
The Cellectar Biosciences share price today is 2.6100.
What Is the Stock Symbol for Cellectar Biosciences Inc
The stock symbol (or 'ticker') for Cellectar Biosciences Inc is "CLRB."
What Stock Exchange Does Cellectar Biosciences Inc Trade On?
Cellectar Biosciences Inc is listed and trades on the NASDAQ stock exchange.
Is Cellectar Biosciences Inc a Good Stock to Buy?
Determining whether Cellectar Biosciences (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.5600
2.6363
52 wk Range
2.2000
6.5200
CLRB is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.56002.6363
52 wk Range
2.20006.5200
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
CLRB Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
11.5000
Upside
+342.31%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
3 analysts have revised their earnings upwards for the upcoming period
Form 4 Cellectar Biosciences Inc For: 8 July- Investing.com
Form 13G CELLECTAR BIOSCIENCES For: 5 June- Investing.com
- Cellectar Biosci receives Investment Bank Analyst Rating Update
- Investing.com
Pro 
Form 4 Cellectar Biosciences Inc For: 10 July- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Analyst Ratings
4 Buy
0 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 11.5000
(+342.31% Upside)
Cellectar Biosciences Inc Earnings Call Summary for Q2/2026
- Cellectar posted Q2 2026 loss of $0.57/share, missing analyst estimates of $0.48, though shares rose 3.85% on stronger cash position of $34M.
- Company secured financing providing $35M upfront with potential for $140M total capital through warrant tranches at $2.65 strike price.
- Site activation began for confirmatory Phase III Waldenstrom's macroglobulinemia study; FDA submission planned mid-2027 with 6-month review expected.
- Management targets 10-20 sites open with initial enrollment by submission; iopofosine showed 79.2% major response rate in post-BTK inhibitor cohort.
- R&D spending surged 92% to $4.6M as CLR 125 triple-negative breast cancer program dosed first patients; initial data expected late 2026 or early 2027.
Last Updated: 13/08/2026, 14:32
Read Full TranscriptEarnings
Latest Release
13/08/2026
EPS / Forecast
-0.57 / -0.48
Revenue / Forecast
-- / --
Compare CLRB to Peers and Sector
Metrics to compare | CLRB | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCLRBPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.9x | −3.7x | −0.4x | |
PEG Ratio | −0.01 | 0.04 | 0.00 | |
Price/Book | 0.7x | 2.5x | 2.6x | |
Price / LTM Sales | - | 7.3x | 3.1x | |
Upside (Analyst Target) | 303.8% | 198.0% | 48.4% | |
Fair Value Upside | Unlock | −0.2% | 6.5% | Unlock |
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company’s lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom’s macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin’s lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. It also develops CLR 121125, an iodine-125 Auger-emitting radioconjugate program; and CLR 225, an actinium-225 based radioconjugate program. The company has collaborative with Orano Med to develop alpha emitter lead-212 conjugated to phospholipid ether series; and LegoChem Bio. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Cellectar Biosciences (NASDAQ: CLRB) Share Price Today?
The Cellectar Biosciences stock price today is 2.6000 USD.
What Stock Exchange Does Cellectar Biosciences (CLRB) Trade On?
Cellectar Biosciences is listed and trades on the Nasdaq Stock Exchange.
What Is the Ticker (Stock Symbol) for Cellectar Biosciences?
The stock symbol (also called a 'ticker') for Cellectar Biosciences is "CLRB."
What Is the Current Cellectar Biosciences Market Capitalisation?
As of today, Cellectar Biosciences (NASDAQ: CLRB) market cap is 20.7800M USD.
What Is Cellectar Biosciences's (CLRB) Earnings Per Share (TTM)?
The Cellectar Biosciences EPS is currently -6.3455 (Trailing Twelve Months).
When Is the Next Cellectar Biosciences Earnings Date?
Cellectar Biosciences's next earnings report will be released on 29/10/2026.
Is CLRB a Buy or Sell From a Technical Analyst Perspective?
Based on today's Cellectar Biosciences moving averages and other technical indicators, the daily buy/sell signal for CLRB stock is Strong Buy.
How Many Times Has Cellectar Biosciences Stock Split?
Cellectar Biosciences has split 6 times. (See the CLRB stock split history page for full effective split date and price information.)
How Many Employees Does Cellectar Biosciences Have?
Cellectar Biosciences has 11 employees, based on their latest Companies House report.
What is the current trading status of Cellectar Biosciences (NASDAQ: CLRB)?
As of 14/08/2026, Cellectar Biosciences (CLRB) is trading at a share price of 2.6000 USD, with a previous close of 2.4800 USD. The stock has fluctuated within a day range of 2.5600 USD to 2.6363 USD, while its 52-week range spans from 2.2000 USD to 6.5200 USD.
What Is Cellectar Biosciences (CLRB) Price Target According to Analysts?
The average 12-month price target for Cellectar Biosciences is 11.5000 USD, with a high estimate of 15 USD and a low estimate of 10 USD. 4 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +342.31% Upside potential.
What Is the CLRB Premarket Price?
CLRB's last pre-market stock price is 2.5657 USD. The pre-market share volume is 20.0000, and the stock has decreased by 0.0857, or 3.4600%.
What Is the CLRB After Hours Price?
CLRB's last after hours stock price is 2.5200 USD, the stock has decreased by -0.0800, or -3.0800%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.